Boosting natural marijuana-like brain chemicals treats fragile X syndrome symptoms

September 25, 2012

American and European scientists have found that increasing natural marijuana-like chemicals in the brain can help correct behavioral issues related to fragile X syndrome, the most common known genetic cause of autism.

The work indicates potential treatments for anxiety and in people with this condition. Results appear online in Nature Communications.

Daniele Piomelli of UC Irvine and Olivier Manzoni of INSERM, the French national research agency, led the study, which identified compounds that inhibit enzymes blocking endocannabinoid transmitters called 2-AG in the striatum and cortex regions of the brain.

These transmitters allow for the efficient transport of at synapses, structures through which information passes between neurons. In , regional synapse communication is severely limited, giving rise to certain cognitive and behavioral problems.

Fragile X syndrome is caused by a mutation of the on the . People born with it are mentally disabled; generally experience crawling, walking and ; tend to avoid eye contact; may be hyperactive or impulsive; and have such notable physical characteristics as an elongated face, flat feet and large ears.

The researchers stress that their findings, while promising, do not point to a cure for the condition.

"What we hope is to one day increase the ability of people with fragile X syndrome to socialize and engage in normal cognitive functions," said Piomelli, a UCI professor of anatomy & neurobiology and the Louise Turner Arnold Chair in the Neurosciences.

The study involved mice genetically altered with FMR1 mutations that exhibited symptoms of fragile X syndrome. Treated with novel compounds that correct 2-AG protein signaling in brain cells, these mice showed dramatic behavioral improvements in maze tests measuring anxiety and open-space acceptance.

While other work has focused on pharmacological treatments for behavioral issues associated with fragile X syndrome, Piomelli noted that this is the first to identify the role endocannabinoids play in the neurobiology of the condition.

Explore further: Fragile X study offers new drug hope

Related Stories

Fragile X study offers new drug hope

September 24, 2012

(Medical Xpress)—An experimental drug can improve sociability in patients with fragile X syndrome and may be helpful as a treatment for autism, according to a study.

Recommended for you

Autism biomarker seen as boon for new treatments

January 11, 2017

Researchers at the UCLA Center for Autism Research and Treatment have identified a signature brain-wave pattern for children with autism spectrum disorder related to a genetic condition known as Dup15q syndrome. The research ...

Lab confirms vitamin D link to autism traits

December 14, 2016

Researchers at The University of Queensland's Queensland Brain Institute have found a link between vitamin D deficiency in pregnancy and increased autism traits.

Neuromotor problems at the core of autism, study says

December 12, 2016

Rutgers neuroscientists have established that problems controlling bodily movements are at the core of autism spectrum disorders and that the use of psychotropic medications to treat autism in children often makes such neuromotor ...

Mutations in life's 'essential genes' tied to autism

December 12, 2016

Genes known to be essential to life—the ones humans need to survive and thrive in the womb—also play a critical role in the development of autism spectrum disorder (ASD), suggests a new study from Penn Medicine geneticists ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

encoded
not rated yet Sep 25, 2012
I knew it!!!!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.